In development: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 331 to 340 of 344

Sort by

Guidance programme: Technology appraisal guidanceRemove Guidance programme: Technology appraisal guidance filter

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia when there is no 17p deletion or TP53 mutation and FCR (fludarabine, cyclophosphamide, rituximab) or BR (bendamustine, rituximab) are suitable (MA partial review of TA663) [ID6291]	Technology appraisal guidance	7 January 2026
Vepdegestrant for treating hormone receptor-positive HER2-negative metastatic breast cancer after endocrine treatment [ID6360]	Technology appraisal guidance	TBC
VER-01 for treating chronic low back pain [ID6638]	Technology appraisal guidance	TBC
Vibostolimab–pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer [ID6382]	Technology appraisal guidance	TBC
Vimseltinib for treating tenosynovial giant cell tumours when surgery is unsuitable TSID 12099	Technology appraisal guidance	TBC
Vocimagene amiretrorepvec with extended-release 5-fluorocytosine for treating recurrent high-grade glioma [ID1425]	Technology appraisal guidance	TBC
Vorasidenib for treating astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after surgery in people 12 years and over [ID6407]	Technology appraisal guidance	28 January 2026
Vosoritide for treating achondroplasia in people 4 months and over [ID6488]	Technology appraisal guidance	TBC
Waldenstrom's macroglobulinaemia - ibrutinib [ID884]	Technology appraisal guidance	22 November 2017
Xevinapant with platinum-based chemotherapy and radiotherapy for untreated locally advanced squamous cell head and neck cancer [ID6199]	Technology appraisal guidance	TBC

Results per page

10
25
50
All